STOCK TITAN

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
NEXGEL, Inc. reschedules its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET due to the Good Friday holiday closure. CEO Adam Levy aims to enhance visibility and convenience for shareholders.
Positive
  • None.
Negative
  • None.

LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced rescheduling its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET. The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call.

Adam Levy, CEO of NEXGEL, commented, “In light of the stock markets being closed to observe the Good Friday holiday, we are moving the reporting of our 2023 financial results to Monday morning before the market open. We hope this creates greater visibility and convenience for our shareholders.”

Fourth Quarter and Full Year 2023 Financial Results Conference Call
Date: Monday, April 1, 2024
Time: 8:30 a.m. ET
Live Call: + 1-800-274-8461 (U.S. Toll Free) or + 1-203-518-9814 (International)
Webcast: Events and Presentations

For interested individuals unable to join the conference call, a replay will be available through April 15, 2024 by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 1155204. An archived version of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com


FAQ

When is NEXGEL rescheduling its financial results conference call for the fourth quarter and full year 2023?

NEXGEL is rescheduling its financial results conference call to Monday, April 1st at 8:30 a.m. ET.

Why is NEXGEL rescheduling its financial results conference call?

NEXGEL is rescheduling its financial results conference call due to the closure of stock markets for the Good Friday holiday.

Who is the CEO of NEXGEL?

Adam Levy is the CEO of NEXGEL.

How can interested individuals access the replay of the conference call?

Interested individuals can access the replay of the conference call by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International) with the code 1155204.

NEXGEL, Inc.

NASDAQ:NXGL

NXGL Rankings

NXGL Latest News

NXGL Stock Data

13.88M
4.93M
22.82%
2.03%
0.42%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
LANGHORNE

About NXGL

nexgel advanced hydrogel solutions in a manufacturer of unique trans-dermal delivery system that was originally developed and fda-approved for the hospital wound care market, and is now being deployed against consumer otc, rx, medical device and cosmetic applications.